Charles River Labs Sets 2026 EPS Outlook at $5.35-$5.85
summarizeSummary
Charles River Laboratories has issued its full-year 2026 earnings per share (EPS) guidance, projecting a range of $5.35 to $5.85. This new financial outlook provides critical forward-looking information for investors, setting expectations for the company's performance in the upcoming fiscal year. While the headline does not provide context relative to analyst consensus, this guidance is a key input for valuation models and will likely influence investor sentiment and trading decisions. This follows the company's 2025 financial results reported in February, which included a net loss primarily due to impairment charges. Traders will now be watching how this guidance compares to current analyst estimates and any subsequent commentary from the company.
At the time of this announcement, CRL was trading at $179.07 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $113.89 to $228.88. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.